1.png
N2OFF: Save Foods Granted Patent Approval in South Africa for its Proprietary Technology
March 28, 2024 08:23 ET | N2OFF Inc.
In 2022, South Africa exported $1.85 billion in citrus, making it the second largest exporter of citrus in the world Neve Yarak, Israel, March 28, 2024 (GLOBE NEWSWIRE) -- N2OFF, Inc. (NASDAQ:...
psychemdicslogo.jpg
Psychemedics Corporation Reports 2023 Financial Results
March 28, 2024 08:20 ET | Psychemedics Corporation
DALLAS, March 28, 2024 (GLOBE NEWSWIRE) -- Psychemedics Corporation (NASDAQ: PMD), the world’s leading provider of hair testing for drugs of abuse, announced today financial results for the year...
biomerica.png
Biomerica InFoods IBS Data to be Presented at the Upcoming Digestive Disease Week (DDW) 2024 Conference
March 28, 2024 08:19 ET | Biomerica, Inc.
Collaborators at the University of Michigan will present new Data on InFoods® IBS in the DDW Irritable Bowel Syndrome (IBS) Clinical Session IRVINE, Calif., March 28, 2024 (GLOBE NEWSWIRE) --...
LogoVislink2022_2.jpg
Abu Dhabi's Inaugural Autonomous Car Race Series Revolutionizes Fan Experience with Vislink and Focal Point VR
March 28, 2024 08:15 ET | Vislink Technologies, Inc.
The Series Represents a Milestone in Immersing Motorsport Audiences into the Action through Innovative Technology Abu Dhabi and Mt. Olive, New Jersey, March 28, 2024 (GLOBE NEWSWIRE) -- Abu Dhabi...
Regency-Logo2012-RGB.jpg
Regency Centers Invites You to Join Its First Quarter 2024 Earnings Conference Call
March 28, 2024 08:15 ET | Regency Centers Corporation
JACKSONVILLE, Fla., March 28, 2024 (GLOBE NEWSWIRE) -- Regency Centers Corporation (“Regency Centers” or the “Company”) (NASDAQ: REG) will announce its First Quarter 2024 earnings results on...
logo.jpg
Processa Pharmaceuticals to Present at the MedInvest Biotech and Pharma Investor Conference
March 28, 2024 08:15 ET | Processa Pharmaceuticals, Inc.
HANOVER, MD, March 28, 2024 (GLOBE NEWSWIRE) -- Processa Pharmaceuticals, Inc. (Nasdaq: PCSA) (“Processa” or the “Company”), a clinical-stage pharmaceutical company focused on developing the next...
molecular.jpg
Molecular Templates Announces $9.5 Million Private Placement Offering and Agreement to Amend Second Tranche of July 2023 Purchase Agreement
March 28, 2024 08:11 ET | Molecular Templates, Inc.
AUSTIN, Texas, March 28, 2024 (GLOBE NEWSWIRE) -- Molecular Templates, Inc. (Nasdaq: MTEM, “Molecular Templates,” or “MTEM”), a clinical-stage biopharmaceutical company focused on the discovery and...
Candel_Logo_FullColor (4).png
Candel Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Corporate Highlights
March 28, 2024 08:05 ET | Candel Therapeutics
On track for topline data from CAN-2409 phase 3 in localized intermediate/high risk prostate cancer, expected in Q4 2024Results from ongoing, first-in-human, phase 1b clinical trial of CAN-3110, in...
Applied Digital - Logo - Horizontal - Black.png
Applied Digital Sets Fiscal Third Quarter 2024 Earnings Conference Call for Wednesday, April 10, 2024 at 9:00 a.m. Eastern Time
March 28, 2024 08:05 ET | Applied Digital Corporation
DALLAS, March 28, 2024 (GLOBE NEWSWIRE) -- Applied Digital Corporation (Nasdaq: APLD) ("Applied Digital" or the "Company"), a designer, builder and operator of next-generation digital infrastructure...
Tevogen Logo Notified.png
Tevogen Bio Reports Series A-1 Preferred Stock Investment at $10 Conversion Price
March 28, 2024 08:05 ET | Tevogen Bio Inc
The shares of Series A-1 Preferred Stock will be issued in the first quarter and will be convertible at a conversion price of $10.00, as opposed to the $4.